{
    "clinical_study": {
        "@rank": "146265", 
        "acronym": "IRIS-1", 
        "arm_group": {
            "arm_group_label": "Intelligent Retinal Implant System", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System\n      (IRIS V1)"
        }, 
        "brief_title": "Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy", 
        "condition": [
            "Retinitis Pigmentosa,", 
            "Cone Rod Dystrophy,", 
            "Choroideremia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Choroideremia", 
                "Retinitis", 
                "Retinitis Pigmentosa", 
                "Retinal Dystrophies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Is 25 years or older at the date of enrolment\n\n          -  Has a confirmed diagnosis of retinitis pigmentosa, choroideremia or cone-rod\n             dystrophy\n\n          -  Has a visual acuity of logMAR 2.3 or worse in both the eyes as determined by a Square\n             Grating scale.\n\n          -  Has functional ganglion cells and optic nerve activity\n\n          -  Has a memory of former useful form vision\n\n          -  Understands and accepts the obligation to present for all schedule follow-up visits.\n\n          -  Has AP eye dimensions that are appropriate with the dimensions of the implant(In\n             Germany: Has an AP eye dimension between 20.5 and 25 mm)\n\n          -  Has head dimensions that are appropriate for visual Interface.\n\n        Exclusion Criteria:\n\n          -  Has a history of severe glaucoma, uveitis, optic neuropathy or any confirmed damage\n             to the optic nerve and/or visual cortex,\n\n          -  Has any disease (other than study allowed diseases) or condition that affects retinal\n             function of the study eye (e.g., central retinal artery/vein occlusion, end-stage\n             diabetic retinopathy, current or prior retinal detachment, infectious or inflammatory\n             retinal disease, etc.),\n\n          -  Has any disease or condition that prevents adequate visualization of the retina of\n             the study eye including, but not limited to, corneal degeneration that cannot be\n             resolved prior to implantation,\n\n          -  Has any disease or condition of the anterior segment of the study eye that prevents\n             adequate physical examination (e.g., ocular trauma, etc.),\n\n          -  Has severe nystagmus,\n\n          -  Has any ocular condition that leads him or her to eye rubbing,\n\n          -  Has any disease or condition that precludes the understanding or communication of the\n             informed consent, study requirements or test protocols (e.g., deafness , multiple\n             sclerosis, amyotrophc lateral sclerosis, neuritis, etc),\n\n          -  Has a history of epileptic seizure,\n\n          -  Has a history of chronic or recurrent infection or inflammation that would preclude\n             participation in the study,\n\n          -  Has a known sensitivity to the contact materials of the implant,\n\n          -  Presents with hypotony in the study eye,\n\n          -  Presents with hypertony in the study eye,\n\n          -  Is pregnant or lactating,\n\n          -  Has another active implanted device (e.g. cochlear implant) or any form of metallic\n             implant in the head (other than dental work) that may interfere with the device\n             function,\n\n          -  Has a diagnosis requiring an active implant (e.g., cardiac pacemaker, vagus nerve\n             implant, etc.),\n\n          -  Has active cancer or a history of intraocular, optic nerve or brain cancer and\n             metastasis,\n\n          -  Is an immune-suppressed subject (e.g., due to HIV positive diagnosis, etc.),\n\n          -  Is carrier of multi-resistant germs,\n\n          -  Requires the use of any of the following medications:\n\n               -  Antimetabolites,\n\n               -  Thrombocyte aggregation reducing therapies (10 days prior until 3 days after\n                  surgery),\n\n               -  Oral anticoagulants (5 days before until 3 days after surgery),\n\n          -  Is participating in another investigational drug or device study that may interfere\n             with the proposed treatment or the ensuring follow-up schedule, (in Germany: Is\n             participating in another investigational drug or device study)\n\n          -  Has any health concern that makes general anaesthesia inadvisable, (in Germany:\n             Patients with an ASA-Score of 3 or higher are excluded from the study)\n\n          -  Is likely requiring MRI scans subsequent to implantation and prior to explantation,\n\n          -  Is likely requiring therapeutic ultrasound subsequent to implantation and prior to\n             explantation of the Retinal Implant\n\n        In Germany: - Patients with recurrent or chronic inflammations or infections are excluded\n        from the study. Specifically patients with the following disorders are excluded:\n\n          -  Common inflammation - severe chronic and consuming diseases that frequently\n             associated with infection (e.g. Crohn disease, Whipple's disease)\n\n          -  Chronic inflammation of the skin in the area of the eye (e.g. dermatitis, rosacea,\n             infection of the skin, herpes zoster)\n\n          -  Chronic inflammation in the area of the eye (e.g. herpes of cornea and/or\n             conjunctiva, recurrent blepharoconjunctivitis, horedolum, chalazion) In Germany: -\n             Has a severe psychological disorder. When in any doubt, an expert assessment needs to\n             be arranged to clarify whether the patient's psychological health is suitable for the\n             trial.\n\n        In Germany: - Has severe renal, cardiac, hepatic etc. organ diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01864486", 
            "org_study_id": "CP4M"
        }, 
        "intervention": {
            "arm_group_label": "Intelligent Retinal Implant System", 
            "intervention_name": "Intelligent Retinal Implant System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 24, 2013", 
        "location": [
            {
                "contact": {
                    "email": "michaela.velikayparel@meduni-graz.at", 
                    "last_name": "Michaela Velikay-Parel, Prof.", 
                    "phone": "+43 316 385 3817"
                }, 
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }, 
                    "name": "Medical University of Graz"
                }, 
                "investigator": {
                    "last_name": "Michaela Velikay-Parel, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ylemer@fo-rothschild.fr", 
                    "last_name": "Yannick LeMer, Dr.", 
                    "phone": "+33 1 480 366 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75012"
                    }, 
                    "name": "Hopital des Quinze Vingts/Fondation Ophtalmologique A. De Rothschild"
                }, 
                "investigator": {
                    "last_name": "Yannick LeMer, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "augenklinik@uke.uni-hamburg.de", 
                    "last_name": "Gisbert Richard, Prof.", 
                    "phone": "+49 40 42803 2301"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20246"
                    }, 
                    "name": "Klinik und Poliklinik f\u00fcr Augenheilkunde Hamburg-Eppendorf"
                }, 
                "investigator": {
                    "last_name": "Gisbert Richard, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy (Title in France: Compensation of Vision With the Intelligent Retinal Implant System (IRIS V1) in Patients With Retinal Dystrophy)", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "France: Institutional Ethical Committee", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Ethics Commission", 
                "Austria: Federal Office for Safety in Health Care", 
                "Austria: Ethikkommission"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All subjects undergo ophthalmological examinations in predefined intervals after implantation. Ophthalmological examinations include funduscopy, slit lamp examination and OCT. All adverse events are recorded and analysed.", 
            "measure": "Number of Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 18 month after implantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01864486"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A series of vision test including grating visual acuity, light localization and contrast sensitivity is performed before and after implantation of the device.", 
            "measure": "Probable benefit", 
            "safety_issue": "No", 
            "time_frame": "Up to 18 months after implantation"
        }, 
        "source": "Pixium Vision SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pixium Vision SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}